Project Details
Description
We propose studies that will develop highly efficient methods for using synthetic glycolipids to activate
and modulate the functions of a type of lymphocyte known as invariant Natural Killer T (iNKT) cells. The
proposed work is strongly focused on the goal of developing clinically relevant iNKT cell-based therapies
for cancer and other diseases.
| Status | Finished |
|---|---|
| Effective start/end date | 7/1/99 → 7/31/22 |
Funding
- National Institute of Allergy and Infectious Diseases: $337,268.00
- National Institute of Allergy and Infectious Diseases: $327,721.00
- National Institute of Allergy and Infectious Diseases: $467,196.00
- National Institute of Allergy and Infectious Diseases: $249,413.00
- National Institute of Allergy and Infectious Diseases: $336,488.00
- National Institute of Allergy and Infectious Diseases: $335,044.00
- National Institute of Allergy and Infectious Diseases: $255,879.00
- National Institute of Allergy and Infectious Diseases: $382,338.00
- National Institute of Allergy and Infectious Diseases: $415,000.00
- National Institute of Allergy and Infectious Diseases: $271,738.00
- National Institute of Allergy and Infectious Diseases: $467,196.00
- National Institute of Allergy and Infectious Diseases: $256,900.00
- National Institute of Allergy and Infectious Diseases: $406,742.00
- National Institute of Allergy and Infectious Diseases: $467,196.00
- National Institute of Allergy and Infectious Diseases: $211,317.00
- National Institute of Allergy and Infectious Diseases: $410,850.00
- National Institute of Allergy and Infectious Diseases: $263,822.00
- National Institute of Allergy and Infectious Diseases: $336,311.00
- National Institute of Allergy and Infectious Diseases: $467,416.00
- National Institute of Allergy and Infectious Diseases: $406,742.00
Fingerprint
Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.